Panbela Therapeutics announces a poster presentation highlighting the results for ivospemin as a polyamine metabolism modulator in ovarian cancer at the American Association for Cancer Research, AACR, which took place April 10, 2024. The work reflects the Company’s on-going collaboration with Johns Hopkins University School of Medicine. “Ivospemin, reduces the viability of human ovarian adenocarcinoma cell lines regardless of their platinum sensitivity and we found that the combination treatment with doxorubicin increases median survival, delays tumor onset, and decreases overall tumor burden compared to either clinical or subclinical doxorubicin dosing schemes.” said Jennifer Simpson, PhD, MSN, CRNP, President & Chief Executive Officer of Panbela. “The continued work by collaborators at Johns Hopkins University School of Medicine is providing the foundation for the initiation of our ovarian cancer program in this year.”
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PBLA:
- Panbela Therapeutics Shifts from Nasdaq to OTCQB Market
- Panbela Announces Transfer to OTCQB Market
- Panbela Therapeutics price target lowered to $5 from $16 at H.C. Wainwright
- Panbela Therapeutics files to sell 255.6K shares of common stock for holders
- Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results